Rheumatoid arthritis

News

Gilead invests $5.1bn in Belgian biotech Galapagos

Belgian biotech Galapagos has signed a shiny new deal with Gilead to develop inflammatory disease and rheumatoid arthritis drugs, where the big US pharma will pay $3.95 billion up front and

News

GSK takes aim at RA market, pitting otilimab against Pfizer ...

GlaxoSmithKline (GSK) has made a serious play for the lucrative rheumatoid arthritis (RA) drug market, announcing the beginning of a phase 3 development programme, involving a new class of

News

AbbVie makes case for Humira follow-on upadacitinib at EULAR

The summer medical conference season is well and truly upon us and much of the focus this week is on the European League Against Rheumatism (EULAR) conference where several big pharma compa

News

Patients switch to lower dose of Pfizer's RA pill after safe...

Pfizer is moving rheumatoid arthritis patients to a lower dose of its blockbuster inflammatory diseases pill Xeljanz in a clinical study, after a safety signal emerged in the trial of patie

News

AbbVie’s JAK inhibitor upadacitinib gets Priority Review

AbbVie’s attempts to diversify beyond Humira have been boosted as its investigational drug upadacitinib has been granted Priority Review by the FDA for moder